Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC

被引：0
|
作者：
Kumar, Pragya
Turati, Virginia
Marusyk, Andriy
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 10期
关键词：
D O I：
10.1158/1538-7445.EVODYN22-B032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B032
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
    Gadgeel, S. M.
    Gandhi, L.
    Riely, G. J.
    Chiappori, A. A.
    West, H. L.
    Azada, M. C.
    CANCER DISCOVERY, 2014, 4 (10) : 1113 - 1113
  • [32] Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
    Madsen, A.
    Jakobsen, K.
    Demuth, C.
    Sorensen, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2255 - S2255
  • [33] Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
    Jamme, Philippe
    Descarpentries, Clotilde
    Gervais, Radj
    Dansin, Eric
    Wislez, Marie
    Gregoire, Valerie
    Richard, Nicolas
    Baldacci, Simon
    Rabbe, Nathalie
    Kyheng, Maeva
    Kherrouche, Zoulika
    Escande, Fabienne
    Copin, Marie Christine
    Cortot, Alexis B.
    CLINICAL LUNG CANCER, 2019, 20 (04) : 297 - +
  • [34] Effectiveness of Alectinib in ALK Rearrangement NSCLC: Real World Data of Peru
    Roque, K.
    Galvez-Nino, M.
    Ruiz, R.
    Heredia, M.
    Castro-Mollo, M.
    Coanqui, O.
    Valdiviezo, N.
    Olivera, M.
    Andrade de Mello, R.
    Mas, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S647
  • [35] Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
    Lin, Jessica J.
    Zhu, Viola W.
    Schoenfeld, Adam J.
    Yeap, Beow Y.
    Saxena, Ashish
    Ferris, Lorin A.
    Dagogo-Jack, Ibiayi
    Farago, Anna F.
    Taber, Angela
    Traynor, Anne
    Menon, Smitha
    Gainor, Justin F.
    Lennerz, Jochen K.
    Plodkowski, Andrew J.
    Digumarthy, Subba R.
    Ignatius, Sai-Hong
    Shaw, Alice T.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1530 - 1538
  • [36] Brigatinib Effective in ALK plus NSCLC
    Leslie, Mitch
    CANCER DISCOVERY, 2017, 7 (01) : 4 - 5
  • [37] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
    Shaw, Alice
    West, Howard
    Socinski, Mark A.
    Ou, Ignatius
    Gandhi, Leena
    Gadgeel, Shirish
    Belani, Chandra P.
    Shirai, Keisuke
    Bazhenova, Lyudmila
    Santos, Edgardo
    Riely, Gregory J.
    Chiappori, Alberto
    Cetnar, Jeremy
    Mekhail, Tarek
    Chao, Bo
    Borghaei, Hossein
    Gold, Kathryn A.
    Johannsdottir, Hrefna
    Ruf, Thorsten
    Boisserie, Frederic
    Henschel, Volkmar
    Zeaiter, Ali
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238
  • [38] Alectinib induced CNS radiation necrosis in an ALK plus NSCLC patient with a remote (7 years) history of brain radiation
    Ou, Sai-Hong Ignatius
    Weitz, Michael
    Jalas, John R.
    Kelly, Daniel F.
    Wong, Vanessa
    Azada, Michele C.
    Quines, Oliver
    Klempner, Samuel J.
    LUNG CANCER, 2016, 96 : 15 - 18
  • [39] Alectinib vs crizotinib in treatment-naive ALK plus NSCLC: CNS efficacy results from the ALEX study
    Gadgeel, S.
    Peters, S.
    Mok, T. S. K.
    Shaw, A. T.
    Kim, D-W.
    Ou, S-H. I.
    Perol, M.
    Dziadziuszko, R.
    Ahn, J. S.
    Rosell, R.
    Zeaiter, A.
    Mitry, E.
    Nueesch, E.
    Balas, B.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
    Xia, Guohao
    Huang, Jiayuan
    Ni, Jie
    Song, Meng
    Zhang, Junling
    Hofman, Paul
    Christopoulos, Petros
    Grenda, Anna
    Huang, Mengli
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 637 - 646
12345